Sandra Hervas Stubbs-rekin lankidetzan egindako argitalpenak (20)

2012

  1. The HIF-1α hypoxia response in tumor-infi ltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy

    Cancer Discovery, Vol. 2, Núm. 7, pp. 608-623

2011

  1. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes

    Cancer Research, Vol. 71, Núm. 3, pp. 801-811

  2. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  3. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  4. Direct effects of type I interferons on cells of the immune system

    Clinical Cancer Research, Vol. 17, Núm. 9, pp. 2619-2627

  5. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  6. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2010

  1. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 11, pp. 1621-1631

  2. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

  3. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2008

  1. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

    Gene Therapy, Vol. 15, Núm. 7, pp. 473-483

  2. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

    Trends in Pharmacological Sciences, Vol. 29, Núm. 8, pp. 383-390

  3. Polly Matzinger's "danger model" finds its predicted danger-denoting self moieties

    Inmunologia, Vol. 27, Núm. 4, pp. 205-211

  4. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906

2007

  1. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615

  2. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2006

  1. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

    Clinical Cancer Research

  2. Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

    Molecular Therapy, Vol. 14, Núm. 1, pp. 129-138